Table 1. Patients characteristics.
| Patients characteristics | N (%) |
|---|---|
| Estrogen Receptor (ER) | |
| Positive | 49 (81.7) |
| Negative | 11 (18.3) |
| Progesterone receptor (PR) | |
| Positive | 41 (68.3) |
| Negative | 19 (31.7) |
| IHQ subtype | |
| Triple negative | 11 (18.3) |
| ER positive, PR negative | 8 (13.3) |
| ER positive, PR positive | 41 (68.3) |
| Adjuvant chemotherapy | |
| Yes | 46 (76.7) |
| No | 14 (23.3) |
| Disease-free interval | |
| ≤ 24 months | 17 (28.3) |
| > 24 months or stage IV at diagnosis | 43 (71.7) |
| Number of chemo lines for metastasic disease | |
| 0 | 36 (60) |
| >1 | 24 (40) |
| Previous chemotherapy | |
| None (or non antracyclines: e.g. CMF) | 15 (25) |
| Anthracyclines | 17 (28.3) |
| Anthracyclines and taxanes | 28 (46.7) |
| Metastatic locations | |
| 1 or 2 | 27 (45) |
| ≥ 3 or hepatic involvement | 33 (55) |
IHQ: inmunohistochemistry CMF: old chemotherapy regimen